NEOADJUVANT СHEMOTHERAPY FOR LOCALLY ADVANCED BREAST CANCER

Area of Science:

• Oncology
• Pharmacology

Background:

• Locally advanced breast cancer (LABC) presents a significant clinical challenge.
• Neoadjuvant chemotherapy is a standard treatment approach for LABC.

Purpose of the Study:

• To evaluate the efficacy and toxicity of neoadjuvant chemotherapy (AC-protocol) combined with Arglabin in LABC patients.
• To compare Arglabin monotherapy against standard AC-protocol chemotherapy.

Main Methods:

• A randomized trial involving 93 LABC patients (stages II-III).
• Three groups received: AC-protocol chemotherapy (control), AC-protocol plus Arglabin, or Arglabin monotherapy.
• Treatment involved 4 courses of neoadjuvant chemotherapy followed by surgery, adjuvant chemotherapy, radiotherapy, and hormone therapy as indicated.

Main Results:

• Neoadjuvant chemotherapy (AC and AC + Arglabin) demonstrated comparable clinical efficacy, significantly outperforming Arglabin monotherapy.
• No significant differences in pathological response were observed across the three treatment groups.
• Arglabin exhibited very low toxicity and appeared to reduce the side effects associated with standard chemotherapy.

Conclusions:

• Combination chemotherapy (AC + Arglabin) is a viable option for LABC treatment, offering similar efficacy to standard AC-protocol with potentially reduced toxicity.
• Arglabin monotherapy is less effective than standard neoadjuvant chemotherapy regimens for LABC.
• Arglabin shows promise as an adjunct to chemotherapy due to its favorable toxicity profile.